Literature DB >> 15522446

Rescue of Ebola virus from cDNA using heterologous support proteins.

Steven Theriault1, Allison Groseth, Gabriele Neumann, Yoshihiro Kawaoka, Heinz Feldmann.   

Abstract

Using the infectious clone for Zaire ebolavirus, the functional specificity of viral proteins of the ribonucleoprotein complex in transcription/replication was investigated by substituting them with heterologous proteins derived from closely (Reston ebolavirus) and distantly related filoviruses (Marburgvirus). The data clearly demonstrated that transcription/replication are neither strictly species-specific nor genus-specific. Protein interactions between the nucleoprotein NP and the virion protein VP35 and the polymerase L and VP35 seemed to be the most critical steps. In contrast to previous data, viral proteins were able to target heterologous filovirus RNA. Together these results indicated that protein-protein interactions are more critical than protein-RNA interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522446     DOI: 10.1016/j.virusres.2004.06.002

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  19 in total

1.  Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.

Authors:  Kristina Maria Schmidt; Michael Schümann; Judith Olejnik; Verena Krähling; Elke Mühlberger
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Ebolavirus polymerase uses an unconventional genome replication mechanism.

Authors:  Laure R Deflubé; Tessa N Cressey; Adam J Hume; Judith Olejnik; Elaine Haddock; Friederike Feldmann; Hideki Ebihara; Rachel Fearns; Elke Mühlberger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-08       Impact factor: 11.205

3.  Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30.

Authors:  Sven Enterlein; Viktor Volchkov; Michael Weik; Larissa Kolesnikova; Valentina Volchkova; Hans-Dieter Klenk; Elke Mühlberger
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Establishment and characterization of plasmid-driven minigenome rescue systems for Nipah virus: RNA polymerase I- and T7-catalyzed generation of functional paramyxoviral RNA.

Authors:  Alexander Freiberg; Lhia Krista Dolores; Sven Enterlein; Ramon Flick
Journal:  Virology       Date:  2007-09-27       Impact factor: 3.616

5.  The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified.

Authors:  A Groseth; J E Charton; M Sauerborn; F Feldmann; S M Jones; T Hoenen; H Feldmann
Journal:  Virus Res       Date:  2008-12-16       Impact factor: 3.303

6.  Filovirus replication and transcription.

Authors:  Elke Mühlberger
Journal:  Future Virol       Date:  2007-03       Impact factor: 1.831

7.  Recovery of avian metapneumovirus subgroup C from cDNA: cross-recognition of avian and human metapneumovirus support proteins.

Authors:  Dhanasekaran Govindarajan; Ursula J Buchholz; Siba K Samal
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  RNA polymerase I-driven minigenome system for Ebola viruses.

Authors:  Allison Groseth; Heinz Feldmann; Steven Theriault; Gülsah Mehmetoglu; Ramon Flick
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome.

Authors:  Priya Luthra; Parameshwaran Ramanan; Chad E Mire; Carla Weisend; Yoshimi Tsuda; Benjamin Yen; Gai Liu; Daisy W Leung; Thomas W Geisbert; Hideki Ebihara; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Host Microbe       Date:  2013-07-17       Impact factor: 21.023

10.  VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Authors:  Sven Enterlein; Kelly L Warfield; Dana L Swenson; David A Stein; Jeffery L Smith; C Scott Gamble; Andrew D Kroeker; Patrick L Iversen; Sina Bavari; Elke Mühlberger
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.